Medtronic plc
NYSE:MDTMedical - Devices
+$0.75 today
- Market cap
- $128.84B
- Beta
- 0.60
- P/E (TTM)
- 21.1
- EPS (TTM)
- $3.74
- Dividend yield
- 3.60%
Volume 6.47M
Average 11.36M
MDT Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Medtronic plcNYSE: MDT
Cash & Equivalents · Q1 FY2027 · quarter ended Jul 2026
Cash & equivalents rises 32.8% from a year ago
Cash & equivalents stood at $1.69B at the end of Q1 FY2027, up 32.8% from a year earlier and down 13.2% from the prior quarter. Over 3 fiscal years it compounded at +8.1% a year.
Context
- Cash & equivalents amounted to 1.8% of total assets at the end of Q1 FY2027, up 0.4 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +32.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2026
- 1.95B USD
- Year-over-year change
- -12.1%
- 4-year CAGR
- -14.9%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2026 | 2026-04-24 | 1.95B | -12.1% |
| FY2025 | 2025-04-25 | 2.22B | +72.7% |
| FY2024 | 2024-04-26 | 1.28B | -16.8% |
| FY2023 | 2023-04-28 | 1.54B | -58.5% |
| FY2022 | 2022-04-29 | 3.71B | — |
Cash & Equivalents vs competitors
How MDT compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +32.8% is the 3rd highest of 9, against a peer median of -6.5%.
- Cash & equivalents amounts to 1.8% of total assets for MDT, versus a peer median of 8.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $3.39B USD | +42.8% | +29.6% | 7.1% | |
| Jun 2026 | $2.91B USD | -11.2% | +56.3% | 21.0% | |
| Jun 2026 | €1.79B EUR | -1.8% | +33.6% | 6.7% | |
| Jul 2026 | $1.69B USD | +32.8% | +8.1% | 1.8% | |
| Sep 2026 | $563.5M USD | -12.8% | +43.7% | 20.8% | |
| Jun 2026 | $539M USD | +0.9% | +30.1% | 1.2% | |
| Jun 2026 | $410M USD | -26.4% | +16.4% | 1.8% | |
AVRAnteris Technologies Global Corp. | Mar 2026 | $283.21M USD | +478.5% | +10.6% | 96.1% |
| Jun 2026 | $205.27M USD | -51.3% | +38.8% | 10.4% | |
| Peer median (excluding MDT) | — | -6.5% | +31.9% | 8.7% | |
Competitors are the stored peer set for MDT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 | FY2026 Apr 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | 3.71B | 1.54B | 1.28B | 2.22B | 1.95B |
| Short-term Investments | 6.86B | 6.42B | 6.72B | 6.75B | 7.27B |
| Net Receivables | 5.55B | 6B | 6.13B | 6.52B | 6.64B |
| Inventory | 4.62B | 5.29B | 5.22B | 5.48B | 5.95B |
| Other Current Assets | 2.32B | 2.43B | 2.59B | 2.86B | 2.97B |
| Total Current Assets | 23.06B | 21.68B | 21.94B | 23.81B | 24.79B |
| Property, Plant & Equipment (Net) | 5.41B | 5.57B | 6.13B | 6.84B | 7.42B |
| Goodwill | 40.5B | 41.43B | 40.99B | 41.74B | 42.59B |
| Intangible Assets | 15.59B | 14.84B | 13.23B | 11.67B | 10.15B |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 6.41B | 7.44B | 7.7B | 7.62B | 8.09B |
| Total Non-current Assets | 67.92B | 69.27B | 68.05B | 67.87B | 68.24B |
| Total Assets | 90.98B | 90.95B | 89.98B | 91.68B | 93.03B |
| Account Payables | 2.28B | 2.66B | 2.41B | 2.45B | 2.64B |
| Short-term Debt | 3.74B | 13M | 1.09B | 2.87B | 1.78B |
| Tax Payables | 704M | 840M | 1.33B | 0 | 914M |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.12B | 1.95B | 2.38B | 2.52B | 2.68B |
| Total Current Liabilities | 12.39B | 9.05B | 10.79B | 12.88B | 11.66B |
| Long-term Debt | 20.32B | 24.29B | 23.88B | 25.59B | 26.12B |
| Deferred Tax Liabilities | 884M | 708M | 515M | 403M | 362M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 4.61B | 5.18B | 4.33B | 4.5B | 4.76B |
| Total Non-current Liabilities | 25.87B | 30.23B | 28.77B | 30.55B | 31.3B |
| Total Liabilities | 38.26B | 39.28B | 39.56B | 43.42B | 42.96B |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | 30.25B | 30.39B | 30.4B | 31.48B | 32.64B |
| Accumulated OCI | (2.27B) | (3.5B) | (3.32B) | (4.28B) | (4.1B) |
| Other Stockholders Equity | 0 | 0 | 0 | (1M) | 0 |
| Minority Interest | 171M | 182M | 206M | 232M | 609M |
| Total Equity | 52.72B | 51.67B | 50.42B | 48.26B | 50.07B |
| Total Debt | 24.11B | 24.36B | 25.02B | 28.52B | 27.96B |
| Net Debt | 20.4B | 22.82B | 23.74B | 26.3B | 26.01B |
Medtronic plc
NYSE:MDT
Intrinsic Alpha fair value
Locked
Current Price
$100.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.